IUSM Alzheimer's Disease Drug Discovery Center: PTC Software

IUSM 阿尔茨海默病药物研发中心：PTC 软件

• 批准号: 10198429
• 负责人: Bruce T Lamb
• 金额: $ 39.37万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-30 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10198429
• 关键词: Alzheimer disease prevention; Alzheimer' s Disease; Alzheimer' s disease model; Animal Disease Models; Award; Basic Science; Biological Markers; Biology; Cause of Death; Clinical Sciences; Computer software; Data; Disease; Funding; Genetic; Goals; Human Pathology; Indiana; Institutes; Intervention; Investments; Lead; Methods; Mission; Parents; Patients; Pharmacologic Substance; Postdoctoral Fellow; Research Personnel; Science; Scientist; Technology; Therapeutic; Translational Research; United States; United States National Institutes of Health; Universities; Validation; Work; base; data sharing; design; disability; drug development; drug discovery; flexibility; medical schools; novel; pre-clinical; sharing platform; translational study

Project Summary Overall: The strategic goal of the Indiana University School of Medicine (IUSM) Alzheimer’s Disease Drug Discovery (ADDD) Center is to integrate sophisticated capability for early drug discovery and contribute to a broader study of emerging Alzheimer’s Disease target hypotheses with the goal of generating new classes of potential therapeutics. The ADDD CENTER will establish itself as a strategic and operational partner for the NIA AMP-AD and MODEL-AD initiatives. By design, this will provide drug discovery capability to bridge the work in target discovery (AMP-AD) with newly discovered lead molecules characterized in AD animal models based on human pathology, genetics and translational biomarkers (MODEL-AD). To accomplish the mission of the ADDD CENTER, we have assembled a team of scientists from Indiana University, Purdue University, and the Indiana Clinical and Translational Sciences Institute (CTSI). This team has considerable expertise in Alzheimer’s disease biology, CNS pharmaceutical drug discovery and development, and scientific excellence in the core discovery technologies that will drive the ADDD CENTER’s contributions and deliverables. A key advantage and differentiated strength of the proposed ADDD CENTER is the primary scientific coordination and administration through IUSM. Specific Aims are: 1. Create a portfolio of characterized AD drug discovery targets representing novel intervention hypotheses that capitalizes on significant investments in basic research and emerging disease understanding. 2. Perform advanced pre-clinical target validation and enablement studies to prioritize the best opportunities for therapeutic discovery. 3. Create quality and well characterized Lead molecules for targets that meet milestone criteria and are opportunities for further translational investment. 4. Create a flexible data sharing platform to enable global researchers with data and Target Enablement Packages to expand on the work of the ADDD CENTER.

项目摘要 总体：印第安纳大学医学院（IUSM）的战略目标 阿尔茨海默氏病药物发现（ADDD）中心是整合复杂的 早期药物发现的能力，并有助于更广泛的新兴研究 阿尔茨海默氏病针对假设的目标是产生新的类别 潜在的治疗学。 ADDD中心将确立自己的战略和 NIA AMP-AD和Model-AD计划的运营合作伙伴。根据设计，这将 提供药物发现能力，以弥合目标发现（AMP-AD）的工作 新发现的基于人类的AD动物模型中特征的铅分子 病理，遗传学和翻译的生物标志物（AD-AD）。 为了完成ADDD中心的任务，我们组建了一个团队 印第安纳大学，普渡大学和印第安纳州临床的科学家 翻译科学研究所（CTSI）。该团队考虑了专业知识 阿尔茨海默氏病生物学，CNS药物发现与发育， 以及将推动ADDD的核心发现技术中的科学卓越 中心的贡献和可交付成果。关键优势和差异化的力量 拟议的ADDD中心是主要的科学协调和 通过iusm进行管理。具体目的是： 1。创建一个特征的AD药物发现目标组合 新颖的干预假设将大量投资资本 基础研究和新兴疾病的理解。 2。执行先进的临床前目标验证和促进研究 优先考虑治疗发现的最佳机会。 3。为满足目标的靶标创造质量和良好的铅分子 里程碑标准是进一步翻译投资的机会。 4。创建一个灵活的数据共享平台，以使全球研究人员使用数据 和目标启用软件包可以扩展ADDD中心的工作。